October 2020

Recombinetics Inc. Completes Joint Venture Transaction with Makana Therapeutics

United States - Minnesota

Recombinetics Inc. formed a joint venture with Makana Therapeutics to develop organs in pigs, or other animals, for transplantation into human patients, which is known as xenotransplantation. Faegre Drinker represented Recombinetics in the deal, which effectively brought together technologies and expertise held by the two participants to accelerate the field of xenotransplantation.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.